Posted by Michael Wonder on 25 Jun 2018
As the drug industry eyes the burgeoning biosimilar market, its united front is starting to crack
25 June 2018 - The pharmaceutical industry’s massive lobbying operation has a well-earned reputation for maintaining a united front on most of the major policy proposals that could affect drug makers and their bottom lines.
But as the industry eyes the burgeoning biosimilar market, that united front is starting to crack.
For years, branded pharmaceutical and biotech manufacturers — largely represented by PhRMA and BIO — have clashed most often with generic manufacturers, largely represented by their own Association for Accessible Medicines.
